Header cover image

Swiss Biotech Stocks

Results

14

0 new

Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.

14 companies

Roche Holding

Market Cap: CHF 242.3b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.

ROG

CHF 282.30

7D

8.6%

1Y

6.3%

Novartis

Market Cap: CHF 201.4b

Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.

NOVN

CHF 104.02

7D

6.3%

1Y

7.0%

Galderma Group

Market Cap: CHF 32.0b

Operates as a dermatology company worldwide.

GALD

CHF 134.70

7D

-3.8%

1Y

77.1%

Sandoz Group

Market Cap: CHF 19.3b

Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.

SDZ

CHF 44.71

7D

-5.2%

1Y

30.8%

Siegfried Holding

Market Cap: CHF 3.6b

Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.

SFZN

CHF 82.80

7D

3.1%

1Y

-29.2%

Tecan Group

Market Cap: CHF 1.9b

Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.

TECN

CHF 148.40

7D

-4.0%

1Y

-46.4%

SKAN Group

Market Cap: CHF 1.2b

Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.

SKAN

CHF 54.20

7D

-1.1%

1Y

-31.5%

Cosmo Pharmaceuticals

Market Cap: CHF 1.1b

Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.

COPN

CHF 66.10

7D

1.7%

1Y

-11.2%

Kuros Biosciences

Market Cap: CHF 1.0b

Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.

KURN

CHF 26.04

7D

8.4%

1Y

48.5%

PolyPeptide Group

Market Cap: CHF 785.2m

Operates as a contract development and manufacturing company in Europe, the United States, and India.

PPGN

CHF 23.80

7D

-2.1%

1Y

-17.1%

Basilea Pharmaceutica

Market Cap: CHF 586.7m

A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.

BSLN

CHF 47.75

7D

3.2%

1Y

5.8%

Newron Pharmaceuticals

Market Cap: CHF 218.0m

A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.

NWRN

CHF 10.92

7D

0.2%

1Y

38.8%

Xlife Sciences

Market Cap: CHF 120.5m

Focuses on the development and commercialization of research projects in the life sciences sector.

XLS

CHF 20.90

7D

0%

1Y

-27.9%

Molecular Partners

Market Cap: CHF 108.4m

A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.

MOLN

CHF 2.90

7D

1.8%

1Y

-28.7%